Clinical Programs

News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Advanced Search
  • Feb 17, 2016
    The Company successfully completed the preclinical episode of the “Joint-Pharma” program, which is aimed at the development of a product combining cannabinoid substances for treating neurological disorders, with an emphasis on Tourette’s syndrome under an orphan drug designation

    Therapix Biosciences announces on February 17th, 2016 of successful results in preclinical studies it has conducted in order to confirm the “entourage effect”. The preclinical study examined...

  • Feb 16, 2016
    Therapix is using technology developed at the Faculty of Medicine of Tel Aviv University, in the context of the Company’s Brain-Bright Program

    Therapix, a specialty pharma company engaged in the development of cannabinoid-based prescribed drugs, announced on February 15th, 2016 that it has entered into a definitive agreement with Ramot,...

  • Dec 22, 2015
    Rhodes Technologies, a Purdue Pharma group company, will supply Therapix with API for the R&D activity, in consideration for a future exclusive supply right and a right of negotiation to marketing the product in the U.S.

    Therapix Biosciences, a company engaged in the development of cannabinoid-based drugs, announces that it has signed an unbinding term-sheet with Rhodes Technologies, a Purdue Pharma group company,...

  • Dec 9, 2015
    Prof. Mechoulam, the “father of medical cannabis” is one of the industry’s pioneers, and was the first to describe the “entourage effect” which serves as basis for one of the Company’s technologies

    Therapix Biosciences announces the appointment of Prof. Raphael Mechoulam as member of the Company’s scientific advisory board, further to the decision to focus the Company’s business strategy...

  • Dec 9, 2015
    Dr. Elran Haber was appointed CEO of the Company and Doron Ben Ami was appointed VP Strategy of the Company

    Therapix, a company engaged in the development of drugs based on the active compounds in cannabis, announces today of key appointments to the Company’s management. Dr. Elran Haber was appointed...

Show 5102550100 per page